The Medical Technology Association of India on January 17 sought the lowering of customs duty to 2.5 percent and the removal of health cess ad valorem on medical devices in the upcoming Union Budget.
Demand help for MSMEs in the sector, higher import duty, increase in healthcare expenditure and restructuring of GST rates to encourage the domestic industry against imports which grew 41 per cent last year.
Medical Technology Association of India (MTaI), which represents research-based medical technology companies in the country, said the government should consider reducing tax burden on medical devices in order to revive the sector.
NPPA said relabelling of stents is not mandatory, and called upon manufacturers and importers to issue revised price lists as quickly as possible in line with its price cap order - a move seen as an attempt to simplify the process ensure continuation of cardiac services to patients.
NPPA said the government can direct any manufacturer to maintain, import or increase supplies of cardiac stents in public interest, and a designated officer of government of both State and Central can enter, search and seize stocks of stents anywhere in the trade channel – if they found to be hoarding them.
The National Pharmaceutical Pricing Authority (NPPA) on Wednesday justifying its price ceiling indicated that it still left enough room for the stent makers to make a decent margin and the drug price control order (DPCO) has provision for separate prices for superior products – two main concerns raised by the stent manufacturers.